Skip to main content
Protagonist Therapeutics, Inc logo

Protagonist Therapeutics, Inc — Investor Relations & Filings

Ticker · PTGX ISIN · US74366E1029 US Manufacturing
Open in API
Filings indexed 641 across all filing types
Latest filing 2017-03-08 Regulatory Filings
Country US United States of America
Listing US PTGX

About Protagonist Therapeutics, Inc

https://www.protagonist-inc.com/

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company that specializes in the discovery and development of peptide-based new chemical entities. The company utilizes its proprietary technology platform to engineer novel oral and injectable peptide therapeutics. Its development pipeline is focused on creating treatments for rare and prevalent diseases, particularly in the areas of hematology and gastroenterology, addressing significant unmet medical needs.

Recent filings

Filing Released Lang Actions
S-8
Regulatory Filings Classification · 95% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans such as equity incentive plans and employee stock purchase plans. The text includes details about the securities to be registered, the plans under which they are offered, indemnification of directors and officers, and incorporation by reference of other filings. It is not a financial report, earnings release, or management discussion, but a regulatory filing related to securities registration. Therefore, it fits best under the category of Regulatory Filings (RNS). The document length is substantial (15,000 characters), and it is not merely an announcement or certification but the actual registration statement filing.
2017-03-08 English
FORM 10-K
Annual Report FY 2016
2017-03-07 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce significant events. The key content is the announcement of financial results for the quarter and year ended December 31, 2016, via a press release attached as Exhibit 99.1. The document itself does not contain detailed financial statements or substantive financial data but rather furnishes a press release with financial highlights. The length is 3292 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, such a document announcing financial results via a press release in a Form 8-K is best classified as an Earnings Release (ER).
2017-03-07 English
SC 13G/A
Major Shareholding Notification
2017-02-15 English
Major Shareholding Notification 2017
Major Shareholding Notification
2017-02-14 English
Major Shareholding Notification 2017
Major Shareholding Notification
2017-02-13 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.